Drug Type AAV based gene therapy |
Synonyms + [1] |
Target |
Mechanism CFI stimulants(complement factor I stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Gyroscope Therapeutics Ltd.Startup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
dry age-related macular degeneration | Phase 2 | US | Gyroscope Therapeutics Ltd.Startup | 14 Jul 2020 |
dry age-related macular degeneration | Phase 2 | FR | 14 Jul 2020 | |
dry age-related macular degeneration | Phase 2 | GB | 14 Jul 2020 | |
dry age-related macular degeneration | Phase 2 | PL | Gyroscope Therapeutics Ltd.Startup | 14 Jul 2020 |
dry age-related macular degeneration | Phase 2 | FR | Gyroscope Therapeutics Ltd.Startup | 14 Jul 2020 |
dry age-related macular degeneration | Phase 2 | AU | Gyroscope Therapeutics Ltd.Startup | 14 Jul 2020 |
Anetoderma | Phase 2 | GB | Gyroscope Therapeutics Ltd.Startup | 17 Dec 2018 |
Anetoderma | Phase 2 | US | Gyroscope Therapeutics Ltd.Startup | 17 Dec 2018 |
Anetoderma | Phase 2 | GB | 17 Dec 2018 | |
Anetoderma | Phase 2 | US | 17 Dec 2018 |
Phase 1/2 | 28 | (jsknoynyii) = czkmfwujdg oqbokpouqa (ofjpdipilj ) View more | Positive | 30 Sep 2021 |